The use of CA-62 biomarker alone or in combination with CEA and CYFRA 21–1 can be as effective methods of lung cancer pre-screening tool before or after LDCT scans or after it as a marker of decision on surgical biopsy was demonstrated by the results obtained in a blind clinical study. The gene discussed is CEACAM5; the disease is lung cancer.